Focal adhesion kinase as an immunotherapeutic target

Area of Science:

• Immunology
• Oncology
• Biochemistry

Background:

• Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase overexpressed in various cancers, including breast, colon, prostate, and lung.
• FAK's overexpression makes it a potential tumor-associated antigen (TAA) for broad-spectrum cancer immunotherapy.
• This study investigates FAK-derived T cell epitopes for their potential to elicit anti-tumor immune responses.

Purpose of the Study:

• To determine if FAK can serve as a TAA recognized by CD4 helper T lymphocytes (HTL).
• To identify specific FAK peptide epitopes capable of inducing anti-tumor cellular immunity.
• To explore the potential of FAK-based immunotherapy for FAK-expressing cancers.

Main Methods:

• Utilized predictive peptide/MHC class II binding algorithms to identify potential T cell epitopes.
• Performed in vitro vaccination of CD4 T lymphocytes from healthy donors and melanoma patients.
• Assessed T cell responses against FAK-expressing tumor cells and lysates.

Main Results:

• Two synthetic peptides, FAK(143-157) and FAK(1,000-1,014), successfully induced HTL responses.
• These T cell responses recognized FAK-expressing tumor cells and dendritic cells in an HLA class II-restricted manner.
• Melanoma patients' CD4 T cells recognized FAK peptides, indicating pre-existing T cell reactivity.

Conclusions:

• FAK functions as a validated TAA.
• Identified peptide epitopes can be used to design T cell-based immunotherapies for FAK-expressing cancers.
• FAK-targeted immunotherapy may be combined with FAK inhibitors for enhanced efficacy.